Ann Lab Med.  2013 Jan;33(1):80-83. 10.3343/alm.2013.33.1.80.

A Case with Coexistence of Major and Minor BCR/ABL Fusion Transcript at Lymphoblastic Crisis of Chronic Myelogenous Leukemia in Patients with Major BCR/ABL Positivity during Chronic Phase

• Park SH
• Chi HS
• Cho YU
• Jang S
• Park CJ
• Im HJ

• KMID: 1781303
• DOI: http://doi.org/10.3343/alm.2013.33.1.80

Abstract

No abstract available.

MeSH Terms

Adolescent
Antineoplastic Agents/therapeutic use
Benzamides/therapeutic use
Chromosome Deletion
Chromosomes, Human, Pair 7
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl/genetics/*metabolism
Humans
Immunophenotyping
Karyotyping
Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*diagnosis/drug therapy/metabolism
Male
Piperazines/therapeutic use
Pyrimidines/therapeutic use
Real-Time Polymerase Chain Reaction
Antineoplastic Agents
Benzamides
Fusion Proteins, bcr-abl
Piperazines
Pyrimidines

Figure

• 

  Fig. 1 Detection of the minor BCR-ABL fusion transcript at the lymphoblastic crisis phase by real-time PCR. The amplification curves for the minor BCR-ABL fusion transcript (A) and ABL1 gene (B) are shown. The ratio of the minor BCR-ABL fusion transcript was calculated as 1.17 normalized copy number (NCN).

• 

  Fig. 2 Analysis of RNA samples collected from the chronic and lymphoblastic crisis phase of CML using the HemaVision screening and split-out kits (Bio-Rad Laboratories). The screening kit produced a single band in the M6 lane (A) whereas the spilt-out kit produced a single 397-base pair band in the M6B lane (B), indicating the presence of the major BCR/ABL fusion transcript (b2a2 type) during the chronic phase. However, during the lymphoblastic crisis phase, the screening kit produced 2 bands in lanes M6 and M8 (C) and the spilt-out kit produced a 397-base pair band in the M6B lane (D) and a 320-base pair band in the M8F lane (E). This indicates the simultaneous presence of both the major (M6B, b2a2 type) and minor (M8F, e1a2 type) BCR/ABL fusion transcripts in this patient.

Reference

1. Oh SH, Park TS, Kim HR, Lee JY, Kim JH, Shin JH, et al. Chronic myelogenous leukemia showing biphenotypic blast crisis followed by lineage switch to B lymphoblastic leukemia. Leuk Res. 2009; 33:e195–e198. PMID: 19446879.

2. Griesshammer M, Heinze B, Hellmann A, Popp C, Anger B, Heil G, et al. Chronic myelogenous leukemia in blast crisis: retrospective analysis of prognostic factors in 90 patients. Ann Hematol. 1996; 73:225–230. PMID: 8959940.

3. Griesshammer M, Heinze B, Bangerter M, Heimpel H, Fliedner TM. Karyotype abnormalities and their clinical significance in blast crisis of chronic myeloid leukemia. J Mol Med (Berl). 1997; 75:836–838. PMID: 9428614.

4. Kawano N, Okuda S, Yoshida S, Kugimiya H, Ito M, Horikawa N, et al. Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation. Int J Hematol. 2011; 94:561–566. PMID: 22057509.

5. Tanaka M, Yamazaki Y, Hattori M, Tsushita K, Utsumi M, Yoshida S. The dual expression of minor and major bcr/abl chimeric mRNA in blast crisis of chronic myelogenous leukemia. Leuk Res. 1996; 20:575–580. PMID: 8795691.